FindTrial
Sign In

Screening study on clinical outcome and prognostic markers of end-stage liver disease

A prospective multicentre study of clinical regression and prognostic markers for end-stage liver disease and their application

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2300070687
Enrollment
Unknown
Registered
2023-04-20
Start date
2021-01-01
Completion date
Unknown
Last updated
2023-06-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

end-stage liver disease

Interventions

Group of end-stage liver disease:None

Sponsors

The First Affiliated Hospital, Zhejiang University School of Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: End-stage liver disease, including patients with compensated cirrhosis, acute and chronic liver failure, including hepatitis B, hepatitis C, autoimmune liver disease, alcoholic liver and other causes of end-stage liver disease.

Exclusion criteria

Exclusion criteria: Exclude co-infection with HIV, pregnant women, age less than 18 or more 70 .

Design outcomes

Primary

MeasureTime frame
Survival Rate;—

Secondary

MeasureTime frame
Infection;decompensation;gastrointestinal bleeding;—

Countries

China

Contacts

Public ContactHongcui Cao

The First Affiliated Hospital, Zhejiang University School of Medicine

hccao@zju.edu.cn+86 13858034217

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026